BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22820661)

  • 1. Melan A (A103) is not a marker of mesothelioma.
    Ordóñez NG; Shen SS; Zenali M; Deavers MT
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
    Ordóñez NG
    Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
    Gao FF; Krasinskas AM; Chivukula M
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
    Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
    Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016).
    Barbieri PG
    Tumori; 2019 Aug; 105(4):361-362. PubMed ID: 30592233
    [No Abstract]   [Full Text] [Related]  

  • 16. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
    Müller AM; Franke FE; Müller KM
    Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
    Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
    Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.